前列腺癌主动监测的随访:严格遵循方案对不符合PRIAS标准的患者仍然重要
该研究评估了荷兰六家教学医院2008至2014年确诊并接受主动监测的前列腺癌患者对PRIAS方案的依从性及其与肿瘤安全性的关系。结果显示74%的患者PSA监测符合方案,但整体符合方案者仅43%,且医院间差异显著(34-60%)。在不符合PRIAS标准的患者中,PSA监测不符合方案与转移风险升高相关(HR 5.25,95%CI 1.02-27.1),而符合标准者中未见显著差异。
要点
- 真实世界中仅43%的主动监测患者随访完全符合PRIAS方案,PSA监测符合率为74%。
- 不符合PRIAS标准的患者中,PSA监测不符合方案与转移风险升高相关(HR 5.25,95%CI 1.02-27.1)。
- 符合PRIAS标准的患者中,不符合方案与符合方案者的转移率无显著差异。
核心结论
- 荷兰大型泌尿外科实践中主动监测的随访强度存在显著差异,日常临床中仅43%的患者接受符合PRIAS方案的随访。
- 在不符合PRIAS标准的患者中,不遵循PRIAS随访方案与更高的转移率相关,表明这些患者选择主动监测时严格遵循方案很重要。
研究设计与样本
- 研究为在荷兰六家教学医院开展的队列研究,纳入2008至2014年活检确诊并接受主动监测的前列腺癌患者。
- 主动监测包括每3-6个月检测前列腺特异性抗原(PSA),以及诊断后1年进行确认性活检,此后每3年一次。
- 分析基于PRIAS纳入标准分为符合PRIAS组和不符合PRIAS组,使用Cox回归分析比较随访是否符合方案与转移风险的关系。
主要发现
- 在主动监测超过6个月的患者中,706/958(74%)的患者PSA监测符合PRIAS方案。
- 整体随访(PSA和重复活检)符合方案者占415/958(43%),各医院间整体符合率范围为34-60%(p<0.001)。
- 在不符合PRIAS标准的患者中,PSA监测不符合方案者发生前列腺癌转移的风险高于符合随访者(风险比5.25,95%置信区间1.02-27.1)。
- 在符合PRIAS标准的患者中,不符合方案与符合方案者的转移率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) is a safe treatment strategy for men with low-risk prostate cancer (PC) when performed in a research setting using strict follow-up. However, less is known about the protocol adherence and outcomes for AS in real-world practice. OBJECTIVE: To evaluate Prostate Cancer Research International Active Surveillance (PRIAS) protocol adherence in a real-world cohort and to relate follow-up intensity to oncological safety. DESIGN, SETTING, AND PARTICIPANTS: Patients with biopsy-detected PC diagnosed from 2008 to 2014 treated with AS at six teaching hospitals in The Netherlands. INTERVENTION: AS included regular prostate-specific antigen (PSA) testing (every 3-6mo) combined with a confirmatory biopsy 1yr after diagnosis and every 3yr thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The proportions of patients complying with the PRIAS biopsy and PSA monitoring protocol were determined. We assessed if PRIAS-discordant follow-up was associated with a higher risk of metastasis compared with PRIAS-concordant follow-up using Cox regression analysis. Analysis was performed for separate risk groups (PRIAS-eligible and PRIAS-ineligible) on the basis of the PRIAS inclusion criteria. RESULTS AND LIMITATIONS: Of all patients on AS for >6mo, 706/958 (74%) had PRIAS-concordant PSA monitoring. Overall concordant follow-up (PSA and repeat biopsy) was observed in 415/958 patients (43%). The percentage of patients with overall concordant follow-up varied between hospitals (range 34-60%; p<0.001). Among PRIAS-ineligible patients, PRIAS-discordant PSA monitoring was associated with a higher risk of developing PC metastases during AS compared with patients with concordant follow-up (hazard ratio 5.25, 95% confidence interval 1.02-27.1). In the PRIAS-eligible population, we found no significant differences regarding rates of metastases between patients with discordant and concordant follow-up. CONCLUSIONS: We observed substantial variation in AS follow-up intensity between large urological practices in the Netherlands. Overall, 43% of patients on AS in daily clinical practice receive PRIAS-concordant follow-up. Noncompliance with the PRIAS follow-up protocol was associated with a higher rate of metastasis among PRIAS-ineligible patients, indicating that strict protocol adherence is important when these patients opt for AS. PATIENT SUMMARY: Fewer than half of patients with prostate cancer on active surveillance are monitored according to the follow-up protocol of the largest ongoing active surveillance study. Lower-intensity monitoring may be less safe for patients who are not in the lowest risk group.
引用
- Soeterik TFW, van Melick HHE, Dijksman LM, et al. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients. Eur Urol Oncol. 2019. PMID: 31411970. doi:10.1016/j.euo.2019.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。